InsidersTradesSigma
Follow the Medtronic plc share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Medtronic plc has recorded 272 insider filings. Market capitalisation: €119.5bn. The latest transaction was reported on 24 August 2026 (Retenue fiscale). Among the most active insiders: Marinaro Michael. All data is accessible without an account.
272
Insider Decl.
n/a
Thresholds
€657,816
2 ops.
Buy Volume
€6m
23 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Medtronic plc Buy (bullish), based on 25 analysts. Average price target: US$98.44.
32Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 10,211 of 29,062 companies
59.0
score / 100
Value54
Quality64
FCF yld4.7%
Earn yld4.1%
EV/EBITDA14.7x
ROE9.8%
Gross mgn65%
Net mgn13%
Debt/EBITDA2.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 August 2026
Declarations272 total
1,084 shares@ US$92.30Ordinary SharesSEC:0001984186-26-000008:0
3,356 shares@ US$85.390.0003% mcap26.6% of flowOrdinary SharesSEC:0001984186-26-000006:0
1,675 shares@ US$85.390.0001% mcap26.0% of flowOrdinary SharesSEC:0002028475-26-000010:0
15,810 shares@ US$85.390.0012% mcap18.5% of flowOrdinary SharesSEC:0001560409-26-000008:0
2,337 shares0Ordinary SharesSEC:0002061393-26-000012:1
6,346 shares0Ordinary SharesSEC:0001964281-26-000004:0
6,923 shares0Ordinary SharesSEC:0002137804-26-000004:1
9,230 shares0Ordinary SharesSEC:0001708062-26-000010:1
10,960 shares0Ordinary SharesSEC:0001984186-26-000006:1
46,147 shares0Ordinary SharesSEC:0001984186-26-000006:2
41,533 shares0Ordinary SharesSEC:0001560409-26-000008:1
5,769 shares0Ordinary SharesSEC:0002028475-26-000010:1
11,537 shares0Ordinary SharesSEC:0002056622-26-000003:0
3,074 shares@ US$85.390.0002% mcap6.1% of flowOrdinary SharesSEC:0001708062-26-000010:0
212 shares@ US$85.390.0000% mcap23.3% of flowOrdinary SharesSEC:0002061393-26-000012:0
1,739 shares@ US$85.390.0001% mcap100.0% of flowOrdinary SharesSEC:0002137804-26-000004:0
2,069 shares@ US$86.880.0002% mcap100.0% of flowOrdinary SharesSEC:0001964281-26-000002:0
3,102 shares@ US$83.150.0003% mcap39.1% of flowOrdinary SharesSEC:0002028475-26-000008:0
3,102 shares@ US$83.150.0002% mcap39.1% of flowCommonSEC144:0001959173-26-005155
4,189 shares@ US$80.44050.0003% mcap8.3% of flowCommonSEC144:0001959173-26-004429
237 shares@ US$83.320.0000% mcap100.0% of flowOrdinary SharesSEC:0002061393-26-000010:0
1,712 shares0Ordinary SharesSEC:0002061393-26-000008:0
2,111 shares0Ordinary SharesSEC:0001188578-26-000003:0
1,508 shares0Ordinary SharesSEC:0002061393-26-000006:0
2,111 shares0Ordinary SharesSEC:0001233158-26-000008:0
25 of 272 declarations
关于 Medtronic plc
Medtronic plc 是全球领先的医疗技术公司之一，在纽约证券交易所上市，股票代码为 MDT。对于法国、比利时和瑞士的投资者而言，它通常符合大型防御性医疗保健公司的特征，受益于人口老龄化、慢性病流行以及向微创手术转变等长期结构性驱动因素。Medtronic 的历史可追溯到 1949 年在明尼阿波利斯成立的一家小型电气维修企业。如今，其运营总部仍设在美国明尼苏达州明尼阿波利斯，这强化了其作为一家拥有全球商业足迹的经典美国医疗保健工业巨头的身份。([medtronic.com](https://www.medtronic.com/en-us/our-company/key-facts.html?utm_source=openai)) 该公司的商业模式涵盖多个核心医疗器械特许经营权，包括心血管解决方案、心脏节律管理、结构性心脏疗法、血管疗法、外科和机器人辅助护理、神经调节、脊柱和糖尿病管理。其产品组合包括经导管主动脉瓣置换系统 (TAVR)、脉冲电场消融 (PFA) 技术、起搏器和植入式心脏设备、血糖监测和胰岛素输送系统，以及手术器械和相关医院技术。这种广度赋予了 Medtronic 规模和韧性，但也意味着公司必须持续投资于研发，并应对严格的监管、报销和临床证据要求。([news.medtronic.com](https://news.medtronic.com/2025-05-21-Medtronic-reports-strong-finish-to-its-fiscal-year-with-its-fourth-quarter-financial-results-announces-dividend-increase?utm_source=openai)) 在竞争方面，Medtronic 仍然是医疗技术领域的全球基准，在医院和医生中拥有广泛的装机量，并在发达市场和新兴市场都占有重要地位。其规模、临床关系和多元化产品组合是相对于 Boston Scientific、Abbott 和 Johnson & Johnson 医疗器械业务等竞争对手的关键优势。近期管理层评论强调了 PFA、TAVR、神经调节和脊柱等增长引擎，这表明公司正有意识地转向更高增长和更高利润的类别。([news.medtronic.com](https://news.medtronic.com/2025-05-21-Medtronic-reports-strong-finish-to-its-fiscal-year-with-its-fourth-quarter-financial-results-announces-dividend-increase?utm_source=openai)) 最近最重要的战略发展发生在 2025 年 5 月，当时 Medtronic 宣布打算将其糖尿病业务分拆为一家新的独立公司，后来于 2025 年 6 月命名为 MiniMed。管理层将此举视为一项投资组合简化措施，旨在使 Medtronic 更专注于其最高价值的特许经营权，同时允许糖尿病部门追求自己的增长路径。Medtronic 还公布了稳健的 2025 财年业绩并增加了股息，这突显了持续的现金生成和股东回报纪律。([news.medtronic.com](https://news.medtronic.com/2025-05-21-Medtronic-announces-intent-to-separate-Diabetes-business?utm_source=openai))
